Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.75 |
| ▸ | TP53 | P04637 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.73 |
| ▸ | MEN1 | O00255 | 7/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13407754 | 0.90 | KDM4E (0.70) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL12682848 | 0.90 | ALDH1A1 (0.70) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL9972172 | 0.84 | MAPT (0.76) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL9972173 | 0.82 | MAPT (0.72) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL5805462 | 0.81 | KDM4E (0.71) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL5804110 | 0.79 | KDM4E (0.74) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL541068 | 0.78 | KMT2A (0.73) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL18826078 | 0.77 | KMT2A (0.76) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL12857883 | 0.77 | KMT2A (0.74) | MAPTTP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL8002634 | 0.76 | MAPT (0.67) | MAPTTP53KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024662-A1 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2014-01-23 | — | — | US | disclosed |
| US-20100087453-A1 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024662-A1 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | ASAH2, LITAF, CYP27A1 | MAPT 1778/4885TP53 227/4885KMT2A 4813/4885 |
| US-20100087453-A1 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | ASAH2, LITAF, CYP27A1 | MAPT 1778/4885TP53 260/4885KMT2A 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.